NEWS

News Articles

SIRPant Immunotherapeutics Announces FDA Clearance of IND Application for SIRPant-MTM for the Treatment of Solid Tumors

December 15, 2023

HUMMELSTOWN, Pa., Dec. 12, 2023 (GLOBE NEWSWIRE) — SIRPant Immunotherapeutics, Inc., a clinical-stage immuno-oncology company focusing on developing next-generation macrophage-based immunotherapies for the treatment of hematological malignancies and solid tumors, today announced that the U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) application for the Company’s lead product candidate, SIRPant-M™,…

Read More

AdvaMed Announces Formation of Medical Imaging Division

December 12, 2023

World’s largest medical imaging companies join world’s largest medtech association WASHINGTON, D.C., – Today, AdvaMed, the Medtech Association, announced the establishment of a new Medical Imaging Technology division focused on advocating on behalf of large and small companies for the essential role of medical imaging technology, radiopharmaceuticals, contrast media, and focused ultrasound devices in our nation’s health care…

Read More

Peter J. Arduini, President and CEO of GE HealthCare, Named Chair of AdvaMed Board of Directors

December 12, 2023

December 11, 2023 | WASHINGTON, D.C., – Today, AdvaMed, the Medtech Association, announced that Peter J. Arduini, president and CEO of GE HealthCare, will become the Chair of the AdvaMed Board of Directors. “The entire board and the global industry AdvaMed represents are very excited to have Peter as our new Board Chair during this critical…

Read More

Using March-In as a Price Control Mechanism Is a “Dangerous Precedent To Set”

December 12, 2023

The White House just announced plans to use Bayh-Dole “march-in rights” to step in and license patent rights of drugs “developed with federal funding” to other manufacturers when the price of the drug is deemed too high. BIO’s Chief Advocacy Officer, Nick Shipley, made the following statement: “Using the Bayh-Dole Act’s march-in process as a mechanism…

Read More

Industry Leader and Globally Recognized Patient Advocate John F. Crowley Appointed to Lead BIO as President & CEO

December 5, 2023

Biotech entrepreneur, company founder, tireless patient advocate, and U.S. Navy combat veteran will guide the life science industry in its mission to feed, fuel and heal the world December 5, 2023 | The Biotechnology Innovation Organization (BIO) is proud to announce that industry leader and military veteran John F. Crowley will be its new President…

Read More

Large Majority of Americans Say Consideration of Clinical Trial Participation Should be a Part of Regular Health Care

December 5, 2023

New National Public Opinion Survey Reveals Willingness to Participate in Clinical Trials; Importance of Trials Reflecting the Population; Concerns About Sharing Personal Health Information Have Grown   Arlington, VA – December 5, 2023 – According to survey findings released today, an overwhelming majority of Americans (87%) agree that health care professionals should discuss clinical trials…

Read More